一、个人简历

周文，上海交通大学药物化学博士，研究员，博士生导师，现任动物抗感染药物和微生物耐药团队首席，农业农村部兽用化学药物和药剂学重点实验室主任，入选广州市人才、上海交通大学SMC-晨星计划、广州中医药大学青年杏林学者，曾担任曾担任广东省“珠江学者”药物化学岗位学科带头人，现任Frontiers in Pharmacology、Veterinary Sciences编委、《天然产物研究与开发》青年编委、J. Med. Chem., Eur. J. Med. Chem., Chem. Comm.等药化顶级期刊通讯评审专家等。兼任山东大学博导、皖南医学院硕导、上海应用技术大学硕导、上海饲料兽药行业协会理事、上海市宠物食品药品专业委员会副主任委员等。

长期从事类药分子设计合成、成药性评价以及药物创制及其关键共性技术研究，主持完成糖类药物候选化合物HSCD-54和蒽醌类NR-20成药性研究、以及北卡罗来纳州Glycan Therapeutics, LLC用于商业化的硫酸肝素类糖芯片构建研究，作为主要完成人参与紫草素肟DMSK-20临床前药物评价。主持参与国家自然科学面上基金、国家自然科学基金联合基金、国家自然科学基金重点项目、国家重大新药创制、上海市生物医药支撑、NIH、FDA等项目21项，培养（含联合培养）博士生3名、硕士生8名、博士后1名。在《Journal of Medicinal Chemistry》《European Journal of Medicinal Chemistry》《Chemical Communication》《Cancer Research》等国内外发论文95篇，其中SCI论文85篇，出版专（译）著5部，获授权专利13项。

二、 联系方式

办公电话：021-34293460

邮      箱：wzhou60@shvri.ac.cn

三、代表论著

1. Lu Y. ^#, Guan T. ^#, Wang S.B. ^#, Zhou C., Wang M.Z., Wang X.Y., Zhang K.Y., Han X.G., Lin J.C., Tang Q., Wang C.M.* and Zhou W.* Novel xanthone antibacterials: Semi-synthesis, biological evaluation, and the action mechanisms [J], Bioorg. Med. Chem., 2023, https://doi.org/10.1016/ j.bmc.2023.117232.

2. Chen W.M. ^#, Zhou C. ^#, Chen J.S., Wang M.Z., Zhou F., Wang C.M. *, Zhang X. *, Zhou W. *, Design and synthesis of epigallocatechin (EGC) analogs selective to inhibit α-amylase over α-glucosidases via the incorporation of caffeine acid and its derivatives, Bioorg.Chem., doi.org/10.1016/j.bioorg.2021.105515, 2022. 119, 105515.

3. Zhou C.^#, Ye W. C.^#, Cao Y.J.^#, Wang M.Z., Qi D.X., Liao G.C., Li H.K., Huang W.P., Chen W.M.* Wang X.Y.,* Zhou W,* A gulose moiety contributes to the belomycin (BLM) disaccharide selective targeting to lung cancer cells, Eur. J. Med. Chem. doi.org/10.1016/j.ejmech.2021.113866，2021, 226:113866.

4. Wang M.Z. ^#, Chen W.M. ^#, Chen J.S., Yuan, S.S., Hu J.J., Han B.X., Huang Y.H.*, Zhou W.* Abnormal saccharides affecting cancer multi-drug resistance (MDR) and the reversal strategies, Eur. J. Med. Chem. 2021, doi.org/10.1016/j.ejmech.1021.113487.

5.He X.G., Li M.L., Ye W.C., Zhou W.* Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC), Bioorg. Chem. 2021, 107, doi.org/ 10.1016/j. bioorg.2020.104574.

6. Chen P.^#, WangS.B.^#, Cao C.Y.^#, YeW.C., WangM.Z., ZhouC., ChenW.M., Zhang X., Zhang K.Y., Zhou W.,^*α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship, Bioorg. Chem .  2021, doi.org/10.1016 /j.bioorg.2021.105295.

7. Fu K.S., Bai Z.F., Chen L.L, Ye W.C., Wang M.Z, Hu J.L, Liu C.H,^* Zhou W, *Antitumor activity and structure-activity relationship of heparanase inhibitors: recent advances, Eur. J. Med. Chem. 2020, 202:112221.

8. Li M.L.^#, Ye W.C.^#, Fu K.S.^#, Zhou C., Shi Y.H, Chen W.M., Hu J.L., Jiang Z.L. *, Zhou W.* Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis, and in vitro and in vivo antitumor evaluation. Eur. J. Med. Chem., doi.org/10.1016/j.ejmech. 2020, 112509.

9. Zhou L.^#, Chen. W.M.^#, Cao C.Y.^#, Shi Y.H., Ye W.C., Hu J.L., Wang L.L.*, Zhou W.* Design and synthesis of α-naphthoflavone chimera derivatives able to reverse cytochrome P450 CY1B1 (CYP1B1)-mediated drug resistant via targeted CYP1B1 degradation, Eur. J. Med. Chem. doi.org/10.1016/j.ejmech. 2019.112028.

10. Cui J.H., Meng Q., Zhang X., Cui Q., Zhou W.*, Li S.S.* Design and synthesis of new naphthoflavones as CYP1B1 inhibitors to overcome docetaxel-resistance associated with CYP1B1 overexpression, J. Med. Chem. 2015, 58 (8), 3534-3547.

四、专利标准

1) 周文，酶化学合成结构明确的硫酸肝素寡糖的方法, 2021, 中国发明专利，ZL201810539159.09.

2) 周文，李茂林，袁思思，一种3-O-氨基甲酰甘露糖供体衍生物、博来霉素二糖及其前体的制备方法, 2021，中国发明专利，ZL2018105770218.

3) 周文，李茂林，袁思思，一种2-羟基古洛糖受体衍生物、博来霉素二糖及其前体的制备方法，2021，中国发明专利，ZL2018105770932.

4) 周文, 硫酸肝素与FK506共轭物酶化学合成以及应用，2020，中国发明专利，ZL201810 444478.1.

5) 周文，一种取代苄基或取代苯基b-D-己糖醛酸糖苷的制备方法，2020，中国发明专利，ZL201810503213.4.